Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15292MR)

This product GTTS-WQ15292MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15292MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1817MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ4171MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ1259MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ11140MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ10379MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ7266MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13406MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ8340MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW